BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more

BioCentury’s roundup of translational innovations

Spotlight on early-stage solid tumor trials with emerging innate immune targets: ALPK1 and ENPP1

Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature

Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen 

Plus: Gilead’s $4.3B takeout of CymaBay

Immunostimulatory antibody-drug conjugates move from concept to clinical product